Tonix Pharmaceuticals Holding Corp. 8-K

What Happened
Tonix Pharmaceuticals Holding Corp. (TNXP) filed an 8-K on May 1, 2026 disclosing selected preliminary operating results for the quarter ended March 31, 2026 and preliminary financial condition as of April 30, 2026. The company reported approximately $185.5 million in cash and cash equivalents at quarter end, a net loss of about $40.8 million for Q1 2026, and net product revenue of approximately $6.9 million. Tonix says it expects to file its Form 10-Q (quarter ended March 31, 2026) on or about May 11, 2026.

Key Details

• Cash and cash equivalents at March 31, 2026: ~$185.5 million.
• Shares outstanding as of April 30, 2026: 15,540,801.
• Q1 2026 net loss: ~$40.8 million (Q1 2025: $16.8 million).
• Net cash used in operating activities Q1 2026: ~$40.2 million (Q1 2025: $16.6 million).
• Capital expenditures Q1 2026: ~$1.7 million (Q1 2025: $6,000).
• Net revenue from marketed products Q1 2026: ~$6.9 million (Q1 2025: $2.4 million).
  • Zembrace SymTouch and Tosymra: ~$3.2 million (Q1 2025: $2.4M).
  • TONMYA (launched Nov 2025): ~$3.7 million; TONMYA Nov 17–Dec 31, 2025 revenue: ~$1.4M.
• Company raised net proceeds of $17.4 million from equity offerings in Q2 2026 and believes cash at March 31, 2026 plus those proceeds will fund planned operations into Q2 2027.
• Results are preliminary and unaudited; PricewaterhouseCoopers LLP has not audited or reviewed these preliminary figures.

Why It Matters
These disclosures show revenue growth driven by the recent TONMYA launch but a substantially larger quarterly loss and cash burn versus a year ago. The company reports a solid cash balance and says additional equity proceeds extend its runway into Q2 2027—key for investors monitoring funding risk. Because the figures are preliminary and unaudited, investors should wait for the finalized Form 10-Q (expected ~May 11, 2026) for the complete, audited financial picture.